Partner With Us NRI

Windlas Biotech Ltd share Price Today

Company details

6M Return 42.08%
1Y Return 103.47%
Mkt Cap.(Cr) 1,433.95
Volume 49,134
Div Yield 0.80%
OI Chg %
Volume 49,134

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Windlas Biotech announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue from operations stood at Rs 171.3 crore as against Rs 140.7 crore, a growth of 21.7% YoY.
  • EBITDA stood at Rs 22.0 crore as against Rs 16.4 crore YoY, a growth of 33.9% YoY. EBITDA Margin (%) came in at 12.8%.
  • PAT stood at Rs 17.0 crore as against Rs 11.4 crore YoY, a growth of 48.4% YoY. PAT Margin (%) came in at 9.9%.

FY24 Financial Highlights:

  • Revenue from operations stood at Rs 631.0 crore as against Rs 513.1 crore, a growth of 23.0% YoY.
  • EBITDA stood at Rs 78.2 crore as against Rs 60.2 crore YoY, a growth of 29.8% YoY. EBITDA Margin (%) came in at 12.4%.
  • PAT stood at Rs 58.2 crore as against Rs 42.6 crore YoY, a growth of 36.5% YoY. PAT Margin (%) came in at 9.2%.

Commenting on the results, Hitesh Windlass, Managing Director – Windlas Biotech said, “During the fiscal year 2024, the IPM witnessed a YoY growth of 7.6% with volume constituting 0.7%. We are very happy to share that your company has achieved record growth of 23% in FY24.

The strategic decisions made in the preceding years, such as expanding our customer base and launching innovative products, are yielding favorable outcomes in Generic Formulations CDMO vertical. In Trade Generics and Institutional vertical also, your company continues to focus on providing Accessible, Affordable, and Authentic medication to the underserved semi-urban and rural markets in India. Government policies that extend medical coverage to vast number of economically backward Indians through schemes like Ayushman Bharat and Jan Aushadhi are further accelerating Institutional purchases.

In March 2024 we commenced manufacturing at our state-of-the-art injectable facility, which is built to meet international cGMP standards. This facility deepens our focus on complex dosage forms and chronic/sub-chronic therapies and shall cater to all three of our business verticals.

The company achieved its highest-ever earnings per share (EPS) in both FY24 (Rs 27.97, YoY growth 42%) and in Q4FY24 (Rs 8.17, YoY growth 52%) following its listing. Furthermore, we have effectively improved our liquidity position, distributed dividends to our esteemed shareholders and generated substantial net operating cash flows.

Our robust financial performance in FY24 and Q4FY24 is a testament to our dedicated team, strong partnerships, and customer-centric approach. We are confident in our ability to continue this growth trajectory and create long-term value for all stakeholders.”

Adding further, Komal Gupta, CEO & CFO - Windlas Biotech said, “Windlas Biotech remains focused on expanding our capabilities, pursuing expansion in newer geographies, driving innovation and delivering high-quality pharmaceutical products to meet the evolving needs of our customers and patients. Our strategic initiatives and operational efficiencies position us well for sustained growth and value creation.

We are delighted to announce strong FY24 financial results on the back of performance momentum seen consecutively across last five quarters. Q4FY24 recorded Rs 171 crore revenue and Rs 22 crore EBITDA being thus the fifth consecutive quarter of highest ever revenue and EBITDA. The company generated strong net operating cash flows of Rs 109 crore during FY24 and had a healthy liquidity position of Rs 206 crore as on 31st March 2024. The EPS stood at Rs 27.97 and 8.17 per share in FY24 and Q4FY24 depicting a YoY growth of 42% and 52%, respectively. In line with our dividend policy, the company proposed the dividend of Rs 11.4 crore (Rs 5.5 per share) related to FY24.

The growth in Generic Formulation CDMO business vertical is driven by our sustained efforts to attract new customers, increase wallet share with current customers and launch of new products. This vertical achieved a revenue of Rs 481.3 crore in FY24 with a YoY growth rate of 19%; and Rs 127.8 crore in Q4FY24 recording a YoY growth rate of 14%.

Trade Generics and Institutional vertical continues to be robust, propelled by wider product portfolio as well as expansion in distribution network across our target market. Government is targeting to increase the Jan Aushadhi store count by 2.5 times to 25,000 by the end of FY26. This will provide added impetus to our Trade Generics and Institutional business. This vertical achieved a revenue of Rs 122.4 crore in FY24 with a YoY growth rate of 35%; and Rs 34.7 crore in Q4FY24 recording a YoY growth rate of 58%.

Our Exports vertical demonstrated revenue of Rs 27.4 crore in FY24 with a YoY growth rate of 38%; and Rs 8.9 crore in Q4FY24 recording a YoY growth rate of 27%.

In the context of the overall financial performance of the company, the revenue generated during FY24 amounted to Rs 631 crore, growth of 23% YoY and for Q4FY24 we recorded Rs 171 crore, a YoY gain of 22%. The EBITDA for FY24 stood at Rs 78 crore, an uptick of 30% YoY and for Q4FY24 Rs 22 crore, witnessing a growth of 34% YoY. The company's PAT for FY24 amounted to Rs 58 crore, reflecting a YoY increase of 37% and for Q4FY24 stood at Rs 17 crore, a YoY rise of 48%.”

Result PDF

View Other Company Results

Windlas Biotech Ltd shares SWOT Analysis

Strengths (14)

  • Company with high TTM EPS Growth
  • Effectively using its capital to generate profit - RoCE improving in last 2 years
  • Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Weakness (2)

  • MFs decreased their shareholding last quarter
  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (1)

  • Highest Recovery from 52 Week Low

Threats (2)

  • Promoter decreasing their shareholding
  • Increasing Trend in Non-Core Income

Resistance and support

R1 700.6
R2 715.1
R3 723.4


S1 677.8
S2 669.5
S3 655.0
Delivery and volume
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-03-01 565.96 110668 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2024-03-01 564.94 110668 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-02-08 522.39 135363 NSE
Name Category Shares
Ashok Kumar Windlass PROMOTER 21.05%
Vimla Windlass PROMOTER 1.36%
AKW WBL Family Private Trust (through its Trustees Ashok Vimla Trusteeship Services Private Limited) PROMOTER 40.1%


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Windlas Biotech Ltd Stocks COMPARISON

Financials( in Cr) Windlas Biotech Ltd Sun Pharmaceuticals Industries Ltd Divis Laboratories Ltd Cipla Ltd Zydus Lifesciences Ltd
Price 686.10 1,568.65 4,519.80 1,485.50 1,144.45
% Change -3.99 -1.87 -2.53 -1.83 -3.03
Mcap Cr 1,433.95 376,371.68 119,986.68 119,934.37 115,158.45
Revenue TTM Cr 513.08 48,496.85 7,845.00 15,790.60 19,547.40
Net Profit TTM Cr 42.63 9,648.44 1,600.00 2,513.47 3,854.40
PE TTM 24.57 37.67 74.86 28.17 29.84
1 Year Return 103.47 50.11 24.17 46.11 96.78
ROCE 14.23 17.20 16.41 14.76 23.94
ROE 10.70 16.13 12.15 10.66 20.64

Equity Capital: 402.27 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 9,613.00 45,166.00
LAST 3M 98,140.76 59,688.15
LAST 6M 181,004.26 50,573.11
LAST 12M 306,939.06 86,273.69

Windlas Biotech Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Windlas Biotech Ltd (formerly known as Windlas Biotech Private Limited) was incorporated in the year 2001. The Company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world. The company has state-of-the-art manufacturing plant facilities located in Dehradun, Uttarakhand, India. It also has a sales force and distribution network spread across 14 states. The company market its own manufactured authentic nutraceutical, pharmaceutical and Ayurvedic products to serve the semi-urban and rural communities at affordable prices. Apart from this, the company has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports. The company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to this, it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries. Moreover, the company has significant experience in developing and manufacturing generic fixed dose combinations. Its focus has currently been in launching new complex generic products in the chronic therapeutic category linked to lifestyle related disorders. The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drug-device combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency, controlled substances and low-solubility products. Further, the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible. To conclude, the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and R&D, through the stages of process development, manufacturing, sales, and supply chain, to the customer evaluation of products as well as management systems for ensuring consistent quality, efficacy, and safety of products. And hence forth, the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment, in addition to the suppliers approved by its customers.

Registered Address

40/1 Mohabewala Industrial, Area, Dehradun, Uttarakhand, 248110

Tel : 91-135-6608000
Email : grievance:windlasbiotech.com
Website : http://www.windlasbiotech.com

Link Intime India Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 543329
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE0H5O01029

FAQ’s on Windlas Biotech Ltd Shares

You can buy Windlas Biotech Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Windlas Biotech Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jul 19, 2024 03:58 PM the closing price of Windlas Biotech Ltd was Rs.686.10.

The latest PE ratio of Windlas Biotech Ltd as of Jul 19, 2024 03:58 PM is 24.57

The latest PB ratio of Windlas Biotech Ltd as of Jul 19, 2024 03:58 PM is 0.31

The 52-week high of Windlas Biotech Ltd share price is Rs. 794.50 while the 52-week low is Rs. 306.20

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jul 19, 2024 03:58 PM, the market cap of Windlas Biotech Ltd stood at Rs. 1,433.95 Cr.

Download App

Download Our App

Play Store App Store
market app